Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
Abstract Introduction Tralokinumab and dupilumab are biological agents licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment. However, no head-to-head studies of their efficacy have been conducted. This study indirectly co...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-04-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-024-01143-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595013210472448 |
|---|---|
| author | Tiago Torres Anne Sohrt Petersen Ulla Ivens Albert Bosch Vilaro John Stinson José Manuel Carrascosa |
| author_facet | Tiago Torres Anne Sohrt Petersen Ulla Ivens Albert Bosch Vilaro John Stinson José Manuel Carrascosa |
| author_sort | Tiago Torres |
| collection | DOAJ |
| description | Abstract Introduction Tralokinumab and dupilumab are biological agents licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment. However, no head-to-head studies of their efficacy have been conducted. This study indirectly compared the efficacy of tralokinumab and dupilumab, both in combination with topical corticosteroids (TCS), at week 32. Methods An unanchored matching-adjusted indirect comparison was conducted using individual patient data (IPD) from the ECZTRA 3 tralokinumab trial and aggregate data from the LIBERTY AD CHRONOS dupilumab trial. IPD were selected by applying inclusion criteria from LIBERTY AD CHRONOS and weighting to match summary baseline characteristics—age, sex, race, body mass index, disease duration, Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), Dermatology Life Quality Index (DLQI) and SCORing Atopic Dermatitis index—of patients treated with dupilumab. Week 32 outcomes of interest were 50%, 75% or 90% improvements in EASI (EASI-50, EASI-75 and EASI-90), IGA scores of 0 or 1 (IGA 0/1), ≥ 4-point improvement in worst daily pruritus numerical rating scale (NRS) score, and mean improvements in DLQI and the Patient Oriented Eczema Measure (POEM). Results After matching, tralokinumab and dupilumab, both in combination with TCS, showed similar efficacy across clinical response endpoints at week 32 (IGA 0/1, tralokinumab 49.9% vs dupilumab 39.3%; EASI-50, 78.9% vs 77.5%; EASI-75, 71.5% vs 71.9%; EASI-90, 53.3% vs 56.2%). The mean change from baseline in DLQI was statistically significantly larger in the matched tralokinumab plus TCS population than in the dupilumab plus TCS arm (− 12.1 vs − 10.4, p = 0.005). Changes in POEM and worst daily pruritus NRS were similar in the two groups. Conclusion The results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32 weeks of therapy. |
| format | Article |
| id | doaj-art-effdcf10082344f191430a55ef10e778 |
| institution | Kabale University |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-effdcf10082344f191430a55ef10e7782025-01-19T12:11:03ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722024-04-0114498399210.1007/s13555-024-01143-xMatching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic DermatitisTiago Torres0Anne Sohrt Petersen1Ulla Ivens2Albert Bosch Vilaro3John Stinson4José Manuel Carrascosa5Centro Hospitalar Universitário de Santo António, University of PortoLEO Pharma A/SLEO Pharma A/SLEO Pharma A/SLEO Pharma A/SHospital Universitari Germans Trias I Pujol, UAB, IGTPAbstract Introduction Tralokinumab and dupilumab are biological agents licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment. However, no head-to-head studies of their efficacy have been conducted. This study indirectly compared the efficacy of tralokinumab and dupilumab, both in combination with topical corticosteroids (TCS), at week 32. Methods An unanchored matching-adjusted indirect comparison was conducted using individual patient data (IPD) from the ECZTRA 3 tralokinumab trial and aggregate data from the LIBERTY AD CHRONOS dupilumab trial. IPD were selected by applying inclusion criteria from LIBERTY AD CHRONOS and weighting to match summary baseline characteristics—age, sex, race, body mass index, disease duration, Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), Dermatology Life Quality Index (DLQI) and SCORing Atopic Dermatitis index—of patients treated with dupilumab. Week 32 outcomes of interest were 50%, 75% or 90% improvements in EASI (EASI-50, EASI-75 and EASI-90), IGA scores of 0 or 1 (IGA 0/1), ≥ 4-point improvement in worst daily pruritus numerical rating scale (NRS) score, and mean improvements in DLQI and the Patient Oriented Eczema Measure (POEM). Results After matching, tralokinumab and dupilumab, both in combination with TCS, showed similar efficacy across clinical response endpoints at week 32 (IGA 0/1, tralokinumab 49.9% vs dupilumab 39.3%; EASI-50, 78.9% vs 77.5%; EASI-75, 71.5% vs 71.9%; EASI-90, 53.3% vs 56.2%). The mean change from baseline in DLQI was statistically significantly larger in the matched tralokinumab plus TCS population than in the dupilumab plus TCS arm (− 12.1 vs − 10.4, p = 0.005). Changes in POEM and worst daily pruritus NRS were similar in the two groups. Conclusion The results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32 weeks of therapy.https://doi.org/10.1007/s13555-024-01143-xAtopic dermatitisDupilumabMatching-adjusted indirect comparisonTopical corticosteroidsTralokinumab |
| spellingShingle | Tiago Torres Anne Sohrt Petersen Ulla Ivens Albert Bosch Vilaro John Stinson José Manuel Carrascosa Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis Dermatology and Therapy Atopic dermatitis Dupilumab Matching-adjusted indirect comparison Topical corticosteroids Tralokinumab |
| title | Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis |
| title_full | Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis |
| title_fullStr | Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis |
| title_full_unstemmed | Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis |
| title_short | Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis |
| title_sort | matching adjusted indirect comparison of the efficacy at week 32 of tralokinumab and dupilumab in the treatment of moderate to severe atopic dermatitis |
| topic | Atopic dermatitis Dupilumab Matching-adjusted indirect comparison Topical corticosteroids Tralokinumab |
| url | https://doi.org/10.1007/s13555-024-01143-x |
| work_keys_str_mv | AT tiagotorres matchingadjustedindirectcomparisonoftheefficacyatweek32oftralokinumabanddupilumabinthetreatmentofmoderatetosevereatopicdermatitis AT annesohrtpetersen matchingadjustedindirectcomparisonoftheefficacyatweek32oftralokinumabanddupilumabinthetreatmentofmoderatetosevereatopicdermatitis AT ullaivens matchingadjustedindirectcomparisonoftheefficacyatweek32oftralokinumabanddupilumabinthetreatmentofmoderatetosevereatopicdermatitis AT albertboschvilaro matchingadjustedindirectcomparisonoftheefficacyatweek32oftralokinumabanddupilumabinthetreatmentofmoderatetosevereatopicdermatitis AT johnstinson matchingadjustedindirectcomparisonoftheefficacyatweek32oftralokinumabanddupilumabinthetreatmentofmoderatetosevereatopicdermatitis AT josemanuelcarrascosa matchingadjustedindirectcomparisonoftheefficacyatweek32oftralokinumabanddupilumabinthetreatmentofmoderatetosevereatopicdermatitis |